Insulin-like growth factor 1 (IGF-1)-induced Twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor

HAL Id: hal-02682538

https://hal.inrae.fr/hal-02682538

Submitted on 1 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Insulin-like growth factor 1 (IGF-1)-induced Twist expression is involved in the anti-apoptotic effects of the

IGF-1 receptor

Joëlle Dupont, Ana M. Fernández, Charlotta A. Glackin, Lee Helman, Derek Leroith

To cite this version:

Joëlle Dupont, Ana M. Fernández, Charlotta A. Glackin, Lee Helman, Derek Leroith. Insulin-like

growth factor 1 (IGF-1)-induced Twist expression is involved in the anti-apoptotic effects of the IGF-1

receptor. Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology,

2001, 276 (28), pp.26699-26707. �10.1074/jbc.M102664200�. �hal-02682538�

Insulin-like Growth Factor 1 (IGF-1)-induced Twist Expression Is Involved in the Anti-apoptotic Effects of the IGF-1 Receptor*

Received for publication, March 26, 2001, and in revised form, April 23, 2001 Published, JBC Papers in Press, April 25, 2001, DOI 10.1074/jbc.M102664200

Joe¨lle Dupont‡, Ana M. Fernandez‡, Charlotta A. Glackin§, Lee Helman

, and Derek LeRoith‡

From the ‡Section on Molecular and Cellular Physiology, Clinical Endocrinology Branch, NIDDK,

and the

Pediatric Oncology Branch, NCI, National Institutes of Health, Bethesda, Maryland 20892-1758 and the

§Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010

In this study we investigated the molecular mecha- nisms whereby insulin-like growth factor 1 (IGF-1) in- duced Twist gene expression and the role of Twist in the anti-apoptotic actions of the IGF-1 receptor. In NIH-3T3 fibroblasts overexpressing the human IGF-1 receptor (NWTb3), treatment with IGF-1 (10

) for 1 and 4 h increased the level of Twist mRNA as well as protein by 3-fold. In contrast, insulin at physiological concentra- tions did not stimulate Twist expression in NIH-3T3 fi- broblasts overexpressing the human insulin receptor.

The IGF-1 effect was specific for the IGF-1 receptor since, in cells overexpressing a dominant negative IGF-1 receptor, IGF-1 failed to increase Twist expression. Pre- incubation with the ERK1/2 inhibitor U0126 or expres- sion of a dominant negative MEK-1 abolished the effect of IGF-1 on Twist mRNA expression in NWTb3 cells, suggesting that Twist induction by IGF-1 occurs via the mitogen-activated protein kinase signaling pathway. In vivo, IGF-1 injection increased the mRNA level of Twist in mouse skeletal muscle, the major site of Twist expres- sion. Finally, using an antisense strategy, we demon- strated that a reduction of 40% in Twist expression de- creased significantly the ability of IGF-1 to rescue NWTb3 cells from etoposide-induced apoptosis. Taken together, these results define Twist as an important fac- tor involved in the anti-apoptotic actions of the IGF-1 receptor.

Insulin and the insulin-like growth factors (IGFs)

exert their biological effects by binding to their respective transmem- brane receptors. Insulin and IGF-1 receptors (IR and IGF-1R, respectively) share the same overall structure. They are com- posed of two extracellular ␣ subunits containing the ligand binding domain and two transmembrane ␤ subunits possessing

tyrosine kinase activity (1, 2). Both receptors are capable of binding insulin and IGF-1, but each receptor binds its own ligand with a 100 –1000 fold higher affinity than that of the heterologous peptide. IR and IGF-1R have intracellular down- stream events that are highly similar. Both receptors phospho- rylate on tyrosine residues the same substrates such as the insulin receptor substrate proteins (1 through 4 (Refs. 3– 6)), Gab-1 (7), and Shc (8), leading to activation of the mitogen- activated protein kinase (MAPK) also defined as extracellular signal regulated kinase (ERK) (9) and the phosphoinositide 3-kinase (PI3K)/Akt (10) pathway. Despite close similarities in their receptor structure and signaling pathways, insulin and IGF-1 have different physiological functions (11–14). Insulin acts primarily as a regulator of metabolism, whereas IGF-1 functions predominantly in the control of cell growth, cell sur- vival and differentiation. In order to understand the molecular basis for the different functions of the IGF-1 and insulin recep- tors, we previously used cDNA microarray expression profiling to identify genes that are differentially regulated by IGF-1 and insulin in mouse fibroblast NIH-3T3 cells.

The mRNA level of Twist was increased more than 2-fold following 90 min of IGF-1 stimulation. However, no increase in Twist expression was observed following insulin stimulation.

Twist belongs to the basic helix-loop-helix family of tran- scription factors, which play a central role in cell type deter- mination and differentiation in both vertebrates and inverte- brates (15). The basic helix-loop-helix proteins are defined by the basic domain that mediates specific DNA binding and the helix-loop-helix domain that acts as a protein-protein interac- tion domain (16). Twist is expressed in mesodermal and cranial neural crest cells during embryogenesis (17). It has been im- plicated in the inhibition of differentiation of multiple cell lineages including muscle (18, 19) and bone (20, 21). For exam- ple, in C2C12 myoblasts (22) as well as in ES cell-derived embryoid bodies (23), Twist expression inhibits muscle differ- entiation. In C2C12 cells, this inhibition was reversible by blocking Twist expression using an antisense Twist oligonu- cleotides. In chicken skeletal muscle, the induction of Twist by hepatocyte growth factor (HGF) enables the satellite cells to proliferate and prevents differentiation (24). Although the in- hibitory mechanisms are as yet unclear, some hypotheses have been proposed. In vitro, some studies show that both murine and Drosophila Twist protein can inhibit the expression and activity of myogenic genes. The suggested mechanisms involve the inactivation of the myogenic factors such as MyoD through heterodimerization with Twist or through inhibition by Twist of myogenic factors binding to DNA (18, 22). Twist has also been demonstrated to inhibit apoptosis in mouse embryonic

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

“advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

储

To whom all correspondence should be addressed: Clinical Endocri- nology Branch, NIDDK, Rm. 8D12, Bldg. 10, National Institutes of Health, Bethesda, MD 20892-1758. Tel.: 301-496-8090; Fax: 301-480- 4386; E-mail: derek@helix.nih.gov.

1

The abbreviations used are: IGF, insulin-like growth factor; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; MEK, mitogen-activated protein kinase/extracellular sig- nal-regulated kinase kinase; MAPK, mitogen-activated protein ki- nase; PARP, poly(ADP-ribose) polymerase; FBS, fetal bovine serum;

PAGE, polyacrylamide gel electrophoresis; TWIAS, Twist antisense;

AS, antisense; HGF, hepatocyte growth factor; IGF-1R, insulin-like growth factor 1 receptor; IR, insulin receptor; DMEM, Dulbecco’s modified Eagle’s medium; kb, kilobase pair(s); Pipes, 1,4-pipera- zinediethanesulfonic acid; Chaps, 3-[(3-cholamidopropyl)dimethyl- ammonio]-1-propanesulfonic acid.

2

J. Dupont, J. Khan, B. H. Qu, P. Metzler, L. Helman, and D.

LeRoith, submitted for publication.

THEJOURNAL OFBIOLOGICALCHEMISTRY Vol. 276, No. 28, Issue of July 13, pp. 26699 –26707, 2001

Printed in U.S.A.

This paper is available on line at http://www.jbc.org

26699

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

fibroblasts that express both E1A and Ha-Ras (C8 MEF), a cell line in which apoptosis has a demonstrated dependence on p53 function (25). It is well known that IGF-1 is a powerful inhib- itor of apoptosis caused by a variety of injuries in various cells.

For example, addition of IGF-1 inhibits apoptosis induced by serum withdrawal in PC12 cells (26), IL-3 withdrawal in he- mopoietic cells (27), as well as by c-Myc overexpression (28), anticancer drugs (29), and transforming growth factor ␤ 1 in fibroblasts (30). However, in different cell types and depending on the apoptotic stimulus, the mechanisms by which the IGF-1R protects cells from apoptosis vary considerably.

In this study, we investigated the mode of IGF-1 action on Twist gene expression and the role of Twist in the anti-apo- ptotic effects of IGF-1. We show that IGF-1 increases mRNA as well as protein levels of Twist in vitro in mouse fibroblasts overexpressing the human IGF-1R (NWTb3), whereas insulin fails to affect Twist expression in mouse fibroblasts overex- pressing the human IR (IR cells). Moreover, in vivo, IGF-1 injections increased Twist expression in mouse skeletal muscle where Twist is predominantly expressed. We also investigated which IGF-1R signaling pathway was involved in the induction of Twist expression using different pharmacological inhibitors and a dominant negative MEK-1 construct. The results indi- cate that the MAPK pathway is primarily involved in IGF-1- induced Twist expression. Finally, using an antisense strategy in NWTb3 cells, we show that Twist is positively involved in the IGF-1 inhibition of apoptosis induced by etoposide treatment.

EXPERIMENTAL PROCEDURES

Chemicals and Antibodies—The radionuclide [␣-

P]dCTP (6000 Ci/

mmol) was purchased from PerkinElmer Life Sciences. Recombinant human IGF-1 (rhIGF-1) was a gift of Genentech (South San Francisco, CA). PI3K-specific inhibitor LY 294002 and etoposide were purchased from Sigma. Both MEK1/2-specific inhibitor U 0126 and p38 MAPK- specific inhibitor SB 202190 were from Calbiochem (La Jolla, CA). The stock solutions of pharmacological inhibitors such as LY 294002, U 0126, and SB 202190 were all prepared in Me

SO at a concentration of 1000-fold, so that when they were added to the culture medium, the concentration of Me

SO was below 0.1%. Monoclonal anti-actin (clone AC) was obtained from Sigma. Rabbit polyclonal antibodies to phospho- Akt (Ser

), Akt, phospho-Erk1/2 (Thr

/Tyr

), and cleaved caspase-3 were purchased from New England Biolabs Inc. (Beverly, MA). Rabbit polyclonal antibody to PARP, which reacts with the PARP full-length and the 24/31-kDa, cleaved PARP product, was from Oncogene (Cambridge, MA). Rabbit polyclonal antibody to Erk1 (C16) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All antibodies were used at a 1/1000 dilution in Western blot- ting. The dominant negative construct of MEK-1 (pCDNAIII-MEKA) was kindly provided by Dr. J. S. Gutkind (NIDCR, National Institutes of Health, Bethesda, MA). Rabbit polyclonal antibodies to Twist and the Twist antisense pcDNA3 construct were kindly donated by Dr. C. A. Glackin (Division of Molecular Medicine, Loma Linda University, Loma Linda, CA).

Cell Culture and Stable Transfection—MCF-7, COS-7, C2C12, and PC3 cells were obtained from ATCC (Rockville, MD). The parental mouse embryonic fibroblast NIH-3T3 cell line expresses ⬃ 16 ⫻ 10

IGF-IR/cell (31). The NWTb3 cell line established in our laboratory expresses the normal human IGF-IR at a level of ⬃ 4 ⫻ 10

receptors/

cell (31). The NKR1 cell line, where the Lys

residue at the ATP- binding site was replaced by arginine (NKR1 mutant) (32), expresses the dominant-negative human IGF-IR ( ⬃ 3–7 ⫻ 10

receptors/cell). The IR cell line, a gift from Dr. S. Taylor (National Institutes of Health, Bethesda, MD), expresses the human wild-type IR at a level of about 2 ⫻ 10

receptors/cell (33). The parental NIH-3T3, MCF-7, COS-7, C2C12, and PC-3 cell lines were routinely cultured in Dulbecco’s mod- ified Eagle’s medium (DMEM) supplemented with 10% heat-inacti- vated fetal bovine serum (FBS), 100 units/ml penicillin, 100 ␮ g/ml streptomycin, and 300 ␮g/ml

-glutamine in a humidified atmosphere of 95% air and 5% CO

(37 °C). NWTb3, IR, and NKR1 cells were cultured in the same medium with the addition of Geneticin (0.5 g/liter, Life Technologies, Inc.). For Twist antisense, the transfection method using Effectene (Qiagen, Valencia, CA) was carried out according to the man-

ufacturer’s instructions. Subconfluent NWTb3 cells were transfected with either hygromycin pcDNA3 (Hygro, negative control) or Twist antisense hygromycin pcDNA3 construct (TWIAS). After 48 h, the cells were cultured in the same medium supplemented with Geneticin (0.5 g/liter) and hygromycin (0.2 g/liter, CLONTECH, Palo Alto, CA).

IGF-1 Stimulation in Vivo—Male C57BL/6j mice weighting 15–20 g were obtained from the Jackson Laboratory (Bar Harbor, ME) at 3 weeks of age. They were maintained on a 12-h light/12-h darkness cycle in a temperature-controlled room and given free access to commercial mouse chow and water. Mice were fasted overnight, anesthetized with avertin (15 ml/kg body weight) intraperitoneally, and abdominal cavi- ties were opened and the inferior vena cava exposed. A bolus of IGF-1 was then injected. For dose responses we utilized 0.5–10 mg/kg IGF-I, and for the time course we utilized 2.0 mg/kg IGF-I.

Western Blot Analysis—Cell lysates were prepared in lysis buffer A (10 m

Tris (pH 7.4), 150 m

NaCl, 1 m

EDTA, 1 m

EGTA, 0.5%

Nonidet P-40) containing various protease inhibitors (2 m

phenyl- methylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin) and phosphatase inhibitors (100 m

sodium fluoride, 10 m

sodium py- rophosphate, 2 m

sodium orthovanadate). Lysates were centrifuged at 12,000 ⫻ g for 20 min at 4 °C, and then the protein concentration in the supernatants was determined using the BCA protein assay. 50

␮ g of total protein samples were electrophoresed in a SDS-PAGE gel and transferred to nitrocellulose membranes. The membranes were blocked with 5% nonfat milk in Tris-buffered saline plus 0.1% Tween for 1 h at room temperature. Blots were probed with the various antibodies as indicated in the figure legends. After extensive wash- ing, bands were detected with the appropriate horseradish peroxi- dase-conjugated secondary antibodies followed by enhanced chemilu- minescence. Densitometry was performed by scanning the radiographs and then analyzing the bands with the MacBas version 2.52 software (Fuji Photo Film U.S.A., Inc.).

Cleavage of Poly(ADP-ribose) Polymerase (PARP) and Caspase-3—

PARP catalyzes the ADP-ribosylation of nuclear proteins at the sites where DNA strands break spontaneously and thereby facilitates the repair of this DNA damage (34). A critical step in the regulation of apoptosis is the proteolytic inactivation of PARP by caspases (34).

Hygro and TWIAS cells were plated in 100-mm dishes in DMEM sup- plemented with 10% FBS. After 16 h of incubation, medium was changed to DMEM with 1% FBS and cells were treated or not with 25

␮

etoposide. Etoposide is a topoisomerase II inhibitor that induces cell cycle arrest or apoptosis when applied in high concentrations (35). After 2 days of treatment, IGF-1 (10

) was added or not for 24 h and cell lysates were prepared in the lysis buffer containing 50 m

Pipes (pH 6.5), 2 m

EDTA, 0.1% Chaps, 5 m

dithiothreitol, 20 ␮ g/leupeptin, 10

␮g/ml pepstatin, 10 ␮g/ml aprotinin, and 1 m

phenylmethylsulfonyl fluoride. The cleavage of PARP and caspase-3 in Hygro and TWIAS cells were analyzed by immunoblotting with anti-PARP and anti-cleaved caspase-3 antibodies.

Analysis of Apoptotic and Necrotic Cell Populations—Cells (Hygro and TWIAS) were washed twice in Hepes buffer (10 m

HEPES, 140 m

NaCl, and 2.5 m

CaCl

) at room temperature as described before (36). Cells were resuspended in 0.2 ml of Hepes buffer supplemented with 2 ␮l of annexin-V-FLUOS (Roche Molecular Biochemicals) and 5 ␮l of 7-amino-actinomycin solution (Via-Probe; PharMingen) and were incubated for 15 min at room temperature in the dark. The staining was analyzed by flow cytometry using a FACSCalibur (Becton Dickinson, Mountain View, CA).

Northern Blot—At the indicated times after treatment with IGF-1, mouse tissues were excised and frozen immediately. Total RNA from tissue was extracted using TRIzol reagent according to the manufac- turer’s instructions. The same technique was used to isolate total RNA from cells stimulated or unstimulated. 20 ␮ g of total RNA from tissue or cells was separated by denaturing formaldehyde electrophoresis, then transferred by capillary blot to positively charged nylon membrane overnight, and immobilized by exposure to UV light. Blots were prehy- bridized for 2 h at 42 °C in a buffer containing formamide 50%, 5 ⫻ Denhardt’s, 1% SDS, 5 ⫻ SSC, and 100 ␮l/ml salmon sperm and hybridized overnight at the same temperature with 2 ⫻ 10

cpm/ml [

P]dCTP-labeled DNA probe in a buffer containing 50% formamide, 2.5 ⫻ Denhardt’s, 1% SDS, 5 ⫻ SSC, and 100 ␮ l/ml salmon sperm. The Twist

P-labeled probe using the Rediprime labeling kit (Amersham Pharmacia Biotech) was generated from cDNA of Twist obtained from a microarray study (clone ID 479 367 from Research Genetics, Hunts- ville, AL). Finally, blots were washed to high stringency and hybrid- ized radioactivity was measured using a PhosphoImager apparatus (FujiFilm, Stamford, CT). Autoradiography was also carried out at

⫺ 70 °C. The integrity and the quantification of different transcripts

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

were assessed using the human RNA 18 S probe from Ambion, Inc.

(Austin, TX).

Transient Transfection of MEK-1 Dominant Negative Construct—

NWTb3 cells were seeded the day before the transfection. Cells were then transiently transfected using the Effectene transfection reagent (Qiagen, CA) according to the manufacturer’s instructions with 1 ␮g of a MEK-1 dominant negative construct (MEK-1 ( ⫺ / ⫺ ) or an empty vector (empty vector). 24 h after transfection, cells were switched to serum-free medium (DMEM) for 16 h, followed by the addition of IGF-1 (10

, 90 min), and then total RNA was extracted. In order to check ERK1/2 phosphorylation in NWTb3 cells transfected with the MEK-1 ( ⫺ / ⫺ ) construct and compare with cells transfected with vector alone, cells were starved overnight 24 h after transfection and stimulated with IGF-I (10

, 10 min at 37 °C). Protein extracts were prepared as described previously, and Western blot analyses were performed with anti-phospho Erk-1/2 antibody to detect Erk-1/2 phosphorylation in- duced by IGF-I stimulation as well as with an Erk-1 antibody to detect Erk-1/2 protein levels.

RESULTS

Differential Effect of IGF-1 and Insulin on Twist mRNA Expression in Mouse Fibroblasts—To characterize the differen- tial effects of insulin and IGF-1 on Twist expression in NIH- 3T3 fibroblasts, cells overexpressing either the human IR (33) or IGF-1 receptor (NWTb3, Ref. 31) were treated with various concentrations of insulin or IGF-1, respectively. Expression of Twist was then determined by Northern blot analysis. As shown in Fig. 1A, incubation for 90 min with IGF-1 (10

) or (10

) increased the abundance of Twist mRNA in NWTb3 cells by ⬃ 2- and ⬃ 3-fold, respectively. Interestingly, in IR cells, treatment with insulin (10

) or (10

) for 90 min failed to increase Twist mRNA levels (Fig. 1B). However, a very high concentration of insulin (10

) increased Twist mRNA. Thus, physiological concentrations of IGF-1 and non-physiological concentrations of insulin stimulate Twist mRNA expression in NWTb3 or IR fibroblasts, respectively.

In order to demonstrate that IGF-1 increases Twist expres- sion through the IGF-1R, NIH-3T3 parental cells and a cell line overexpressing the dominant negative human IGF-IR, NKR1 cells (32) were stimulated with IGF-1 (10

) for 90 min. It has been previously shown that NIH-3T3 cells express ⬃ 16,000 IGF-IR/cell as compared with the NWTb3 cells ( ⬃ 4 ⫻ 10

IGF-IR/cell). As shown in Fig. 2, the increase in Twist expres- sion in response to IGF-1 was observed only in NWTb3 cells overexpressing normal IGF-IRs as compared with parental NIH-3T3 and NKR1 cell lines. The lack of identifiable response in the parental NIH-3T3 cells is mostly due to the fewer num- ber of IGF-I receptors. Taken together, these data demonstrate that IGF-1R activation is necessary to increase Twist expression.

We also studied the level of Twist mRNA and protein in NWTb3 cells treated with IGF-1 for various times. Using Northern blot analysis, we show that IGF-1 (10

) increased Twist mRNA level maximally after 4 h of stimulation. This effect is reduced after 8 h and abolished after 16 h of stimula- F

. 2. Effect of IGF-1R activation on Twist mRNA expression in NIH-3T3 fibroblasts. Serum-starved NIH-3T3 parental, NWTb3, and NKR-1 cells were exposed to IGF-1 (10

) for 90 min. Total RNA was extracted and analyzed by Northern blotting for the expression of Twist. After quantification by densitometry and autoradiography, membranes were stripped and rehybridized with the 18 S ribosomal RNA as a loading control. Results shown are representative of three experiments.

F

. 1. Dose-dependent effects of IGF-1 (A) and insulin (B) on Twist mRNA expression in NIH-3T3 fibro- blasts. Serum-starved NWTb3 (A) and IR (B) cells were stimulated with the indi- cated concentrations of IGF-1 and insulin, respectively, for 90 min. Total RNA was isolated, resolved by agarose gel electro- phoresis, and transferred to a nylon mem- brane. Membranes were hybridized to a cDNA probe for Twist. Signal intensities, determined with a PhosphoImager appa- ratus (FujiFilm), were corrected for differ- ences in loading by dividing the signal intensity for Twist by the signal intensity for 18 S ribosomal RNA. The graphs rep- resent the corrected intensities for the Twist signal. The error bars represent the mean ⫾ S.D. from three separate experiments.

Role of Twist in the Anti-apoptotic Actions of IGF-1R 26701

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

tion (Fig. 3A). We also show that the amount of Twist protein (26 kDa) increased 3-fold after 4 h of IGF-1 treatment (Fig. 3B).

This increase was observed up to 12 h of IGF-1 treatment.

However, after 24 h of stimulation, the effect of IGF-1 was abolished. Thus, the time course for Twist protein expression correlates well with the expression of Twist mRNA induced by IGF-1. These observations demonstrate that the stimulatory effect of IGF-1 on Twist gene expression in NWTb3 cells leads to the production of Twist protein under these conditions.

MAP Kinase Is Involved in IGF-1-induced TWIST Expres- sion—In order to study the signaling pathways involved in IGF-1’s induction of TWIST expression, inhibitors specific for p38, ERK1/2, and PI3K were used. First, we determined the active concentration of each inhibitor. NWTb3 cells were treated for 1 h with the inhibitors prior to the IGF-1 stimula- tion (10

, 10 min). Western blot analysis (Fig. 4A) revealed the dose-dependent inhibition of SB 202190 (p38 pathway), U 0126 (ERK1/2 pathway), and LY 294002 (PI3K pathway), re- spectively, on the IGF-1-induced p38, ERK1/2, and Akt phos- phorylation. As shown in Fig. 4A, 50 ␮

LY 294002 was able to inhibit Akt phosphorylation induced by IGF-1 and in the same manner, 0.5 ␮

U 0126 and 50 ␮

SB 202190 inhibited ERK1/2 and p38 phosphorylation, respectively (Fig. 4A). Western blot analyses, performed to detect all forms of Akt, ERK1/2 and p38 kinases, revealed that protein levels were similar among the samples. Moreover, we found that the same dose of each inhib- itor (50 ␮

LY 294002, 0.5 ␮

U0126, and 50 ␮

SB 202190) also inhibited Akt, MAPK, and p38 in vitro activities respec- tively (data not shown). Fig. 4B indicates that neither PI3K pathway inhibitor LY 294002 nor p38 inhibitor SB 202190 affected IGF-1-induced Twist expression. However, the addi- tion of U0126 abrogated the increase of Twist expression in- duced by IGF-1 stimulation. Thus, in NWTb3 cells, the expres- sion of Twist induced by IGF-1R activation is apparently mediated through the MAPK pathway.

In order to confirm this result, NWTb3 cells were transiently

transfected with a dominant negative MEK-1 construct (MEK-1 ( ⫺ / ⫺ )). Upon IGF-1 stimulation, there was an 80%

reduction in ERK1/2 phosphorylation after transfection of the dominant negative construct (Fig. 5A). Northern blot analysis was performed on NWTb3 transfected with MEK-1 dominant negative (MEK-1 ( ⫺ / ⫺ )) or empty vector (empty vector) as a control (Fig. 5B). Upon IGF-1 stimulation, in cells transfected with empty vector, Twist mRNA expression was increased by 2.5-fold as compared with unstimulated cells. However, when NWTb3 cells were transfected with a dominant negative MEK-1, the IGF-1-induced Twist expression was not observed.

Thus, the inhibition of the MAPK pathway, either by a specific ERK1/2 inhibitor (Fig. 4B) or by the expression of MEK-1 dominant negative in NWTb3 (Fig. 5B), results in inhibition of the IGF-1-induced Twist mRNA expression.

Twist Is Involved in the IGF-1 Inhibition of Apoptosis In- duced by Etoposide Treatment in NWTb3 Cells—Twist has been shown to be implicated in the control of diverse develop- mental processes in different tissues as well as inhibition of apoptosis (25). In order to determine the role of Twist in the anti-apoptotic action of IGF-1, we generated Twist antisense clones (TWIAS). The Twist antisense clones were developed by stable transfection of NWTb3 cells with pcDNA3-hygro-TWIAS expression vector as described under “Experimental Proce- dures.” Several hygromycin resistant clones were analyzed by immunoblotting using an anti-Twist antibody. Three clones were selected, designated as AS-1 to AS-3. In parallel, NWTb3 cells were stably transfected with the pcDNA3 hygromycin empty vector and two control clones (hygro1 and 2) were gen- erated. Twist (26 kDa) immunoreactivity was reduced by 40 – 45% in the AS-1, AS-2, and AS-3 compared with the hygro1 and hygro2 clones (Fig. 6A). Control and TWIAS cells were prein- cubated or not with 25 ␮

etoposide for 48 h (a dose that induces apoptosis (35, 38)), and then IGF-1 (10

) was added or not to the medium for an additional 24 h. Apoptosis was determined by annexin-V staining, which measures the trans- F

. 3. Time course of IGF-1 action on the abundance of Twist mRNA (A) and protein (B) in NIH-3T3 fibroblasts. Serum-starved NWTb3 cells were incubated with IGF-1 (10

) for the indicated times. A, total RNA was extracted from the cells, resolved by agarose gel electrophoresis, and transferred to a nylon membrane. Membranes were hybridized to a cDNA probe for Twist, and results were quantified by densitometry using a PhosphoImager apparatus (FujiFilm). 18 S ribosomal RNA was used as a loading control. The corrected densities are expressed as a percent of the value at time 0 (starved cells). The error bars represent the mean ⫾ S.D. from three separate experiments. B, cells were lysed and proteins were separated on SDS-PAGE and immunoblotted with an antibody to Twist. Samples contained equal levels of protein, as confirmed by reprobing the membrane with an anti- ␣ Actin antibody. Immunoreactivity was quantified by scanning densitometry and expressed as percentage of that for unstimulated cells. The results are representative of three independent experiments.

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

location of phosphatidylserine to the outer plasma membrane, one of the earliest detectable events in the induction of apo- ptosis (39). In both control (hygro1) and Twist antisense (TWIAS-2) NWTb3 cells, the percentage of apoptotic cells rep- resented less than 5% in basal state (DMEM with 1% FBS) and about 30% after etoposide treatment for 48 h. IGF-1 treatment (10

) for 24 h decreased the percentage of apoptotic cells to 8 ⫾ 1% (p ⬍ 0.001) and 20 ⫾ 3% in control and Twist antisense cells, respectively. The level of necrotic cells (annexin-V- and 7-amino-actinomycin-positive) was similar (about 10%) in both control and Twist antisense cells under these conditions.

We also determined the level of PARP (Fig. 6C) and caspase-3 cleavage (data not shown). A critical step in the control of the apoptotic DNA fragmentation is the proteolytic inactivation of PARP by caspases (34). In both cell lines, control and Twist antisense, PARP is not cleaved in the basal state whereas treatment with 25 ␮

etoposide results in PARP cleav- age as indicated by the presence of the cleaved PARP product of 31 kDa (Fig. 6C). As shown in Fig. 6C, IGF-1 (10

) treat- ment for 24 h prevents the cleavage of PARP in control but not in Twist antisense cells. We found the same results for the cleaved caspase-3 product (data not shown). These results were confirmed in separate control and Twist antisense clones.

Thus, a reduction of 40% in Twist protein expression reduced significantly the IGF-1 inhibition of the apoptosis induced by etoposide treatment in NWTb3 cells, suggesting a role for Twist in the anti-apoptotic effects of IGF-1.

Twist Expression Is Cell Type- and Tissue-specific—We stud-

ied the pattern of Twist expression in vitro in various cell lines (Fig. 7A) and in vivo in different mouse tissues (Fig. 7B). In vitro, using Northern blot analysis, we detected Twist as a transcript of about 3.5 kb in human cell lines (MCF-7, PC-3, and HEK-293 cells) and as a transcript of about 1.6 kb in mouse fibroblast NWTb3 cell line, respectively. As expected, mouse myoblast C2C12 cells and COS-7 cells do not express Twist (Fig. 7A; Refs. 19 and 22). When all the cell lines studied were stimulated with IGF-1 (10

) for 90 min, Twist expression was increased only in NWTb3 cells suggesting that IGF-1- induced Twist expression is specific to cultured fibroblasts. In vivo, in mouse tissues, we detected Twist as three transcripts (about 1.6, 4, and 4.9 kb). Twist 1.6-kb transcript is mainly expressed in skeletal muscle and in testis (Fig. 7B).

IGF-1 Increases Twist mRNA Expression in Vivo in Mouse Muscle—We also investigated the effect of in vivo IGF-1 injec- tions on mouse skeletal muscle Twist expression. Three-week- old mice (C57bl/6j) were fasted overnight and infused with either saline (0) or IGF-1 via the inferior vena cava at the concentrations and times indicated in Fig. 8 (A and B), respec- tively. Initially, mice were infused with saline (0) or varying concentrations of IGF-1 (0.5–10 mg/kg) for 20 min (Fig. 8A).

IGF-1 (1.5 mg/kg) increased the level of Twist mRNA by 1.4- fold as compared with saline infusion. This increase was max- imal after IGF-1 (2 mg/kg) infusion. The time course of IGF-1’s effect at 2 mg/kg indicated that 20 min is the optimal time to obtain the maximal response of Twist expression to IGF-1 (Fig.

8B). Thus, IGF-1 increases Twist expression in vitro in mouse F

. 4. Determination of the intra-

cellular signaling pathways involved in the IGF-1-induced Twist expres- sion in NIH-3T3 fibroblasts. A, West- ern blot analysis. Inhibition of IGF-1 in- duced p38, ERK1/2, and Akt phosphoryla- tion, respectively, by the p38 inhibitor SB 202190, the MEK1/2 inhibitor U0126, and the PI3K inhibitor LY294002. NWTb3 cells were plated in 100-mm dishes (1 ⫻ 10

cell/dish). Serum-starved cells were pre-treated with SB202190, U0126, and LY294002 for 1 h at the indicated con- centrations and then incubated with or without IGF-1 (10

) for 10 min. p38, ERK1/2, and Akt phosphorylation were immunodetected with phospho-antibodies as described under “Experimental Pro- cedures,” and then the membranes were stripped and re-probed with antibodies that detected the total proteins as a con- trol. Results shown are representative of two experiments. B, effect of LY294002, U0126, and SB202190 on IGF-1-induced Twist expression. Serum-starved NWTb3 cells were pre-incubated for 1 h with the inhibiting concentration of each inhibitor:

50 ␮

LY294002, 0.5 ␮

U0126, or 50 ␮

SB202190 and then stimulated or not with IGF-1 (10

) for 90 min. Total RNA was isolated and analyzed by Northern blotting for the expression of Twist. After quantification by densito- metry and autoradiography, membranes were stripped and probed with the 18 S ribosomal RNA as a loading control. The error bars represent the mean ⫾ S.D.

from three separate experiments.

Role of Twist in the Anti-apoptotic Actions of IGF-1R 26703

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

fibroblasts NIH-3T3 cells but also in vivo in mouse skeletal muscle.

DISCUSSION

The biological effects of IGF-1 and insulin are mediated by distinct but highly homologous cell surface receptors. Despite close similarities in the structure and signaling pathways of their receptors, insulin and IGF-1 have different biological actions. Whereas IR is mainly implicated in metabolic re- sponses, the IGF-1R is primarily involved in mitogenesis, cell differentiation, and other important functions such as anti- apoptosis. The activation of distinct cellular responses by IR and IGF-1R might result in association with different intracel- lular signaling proteins or induction of different signaling me- diators. We were interested in studying the molecular mecha- nism of IGF-1 action on Twist gene expression. We show that, in mouse fibroblast NIH 3T3 cells, the level of Twist mRNA is increased by IGF-1 at physiological concentrations and by in- sulin at only pharmacological doses. Twist has been demon- strated to inhibit muscle differentiation (18) but also to be an anti-apoptotic factor in a mouse embryo fibroblast-derived cell

line (25). Thus, Twist could represent an important molecule involved in mediating IGF-1R-specific cellular responses.

In this study, we used NWTb3 cells, a NIH-3T3-derived cell line overexpressing the normal human IGF-1R (since parental NIH-3T3 cells have far fewer IGF-I receptors and do not show a response of Twist expression to IGF-I stimulation). As control cells, we used a cell line overexpressing tyrosine kinase-defi- cient human IGF-1R, where the lysine 1003 residue at ATP binding site was replaced by arginine (KR mutant; Ref. 32).

This cell line (NKR) was characterized as an IGF-1R dominant negative NIH-3T3-derived cell line. Indeed, it has been re- ported previously that a human IGF-1R cDNA with a point mutation at the ATP binding site is an inactive receptor, un- able to transmit a mitogenic signal, to transform (40), or to protect cells from apoptosis (41). By Northern blot analysis, we showed that IGF-1 was able to induce Twist expression in NWTb3 cells but not in NKR cells. We also showed that, in vivo, IGF-1 injections increased Twist expression in mouse skeletal muscle. Moreover, this effect was abolished in MKR mice that overexpress the negative dominant KR of IGF-1R specifically in F

. 5. Dominant negative MEK-1

abolishes IGF-1-induced Twist mRNA expression in NIH-3T3 fibroblasts.

NWTb3 cells were transiently transfected with pcDNAIII-MEKA, a dominant nega- tive MEK-1 construct (MEK ⫺ / ⫺ ), or vector alone (empty vector) as a control experi- ment. ERK1/2 phosphorylation and protein levels were determined in response to IGF-1 (10

, 10 min) in MEK ⫺ / ⫺ and empty vector cells as described under “Ex- perimental Procedures” (A). After 90 min of IGF-1 stimulation, total RNA was also ex- tracted and analyzed by Northern blotting for the expression of Twist (B). 18 S ribo- somal RNA is shown as loading control.

The error bars represent the mean ⫾ S.D.

from three separate experiments.

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

the muscle (data not shown).

These results indicate that the kinase activity of IGF-1R is essential for the induction of Twist expression in response to IGF-1. In chicken muscle satellite cells, another growth factor, HGF inhibits cell differentiation and stimulates cell proliferation by increasing the expression of Twist and reducing the level of cyclin-dependent kinase inhib- itor p27 (24). However, the signaling pathway of HGF on Twist gene expression was not fully characterized. In the present

study, we found that the ability of IGF-1 to induce Twist expression was blocked by U0126, a specific inhibitor of ERK1/2 kinase, whereas LY294002 (PI3K inhibitor) and SB202190 (p38 MAPK inhibitor) did not block the IGF-1 action on Twist expression. Thus, the pathway used by the IGF-1 system to induce Twist expression acts through the ERK1/2 kinase cascade.

Twist has been described mainly as an anti-myogenic and anti-apoptotic factor. In vitro, C2C12 myoblasts do not nor- mally express Twist (19, 22). However, in Twist-transfected C2C12 myoblast cells, Twist inhibits cellular differentiation but does not affect cellular proliferation (42). In vivo, Twist is expressed in human and mouse muscle but its role has not been fully elucidated (43). Recently, we have shown that the hyp- oplasia found in MKR mice muscle at 3 weeks of age was correlated with an up-regulation of Twist expression and a down-regulation of MyoD as compared with the wild-type ani- mal, suggesting that Twist could also be involved in vivo in mouse muscle differentiation.

Twist-null mice die at day 11.5 post coitum (44). Just prior to death, Twist null mice show a massive wave of apoptosis in the developing somites, a site in which Twist is normally expressed (44). Studies in Drosophila also indicated that Twist might affect the transcription of fi- broblast growth factor receptor, which is implicated in cranio- synostosis (45). Many syndromes of craniosynostosis result from local perturbation of the apoptotic program (46). In C8 mouse embryo fibroblasts (cells expressing both E1A and Ha- RasV12), ectopic expression of Twist has been shown to inhibit the apoptosis induced by serum starvation and contact inhibi- tion (25). In the present work, we generated Twist antisense clones and studied the action of IGF-1 on apoptosis of NWTb3 cells induced by etoposide treatment. Etoposide is a topoi- somerase II inhibitor inducing cell cycle arrest (usually G

-M, although some reports also show G

arrest) or apoptosis when applied at high concentration (35). Some studies demonstrated that the addition of IGF-1 markedly inhibits etoposide-induced apoptosis in p6 cells (BALB/c 3T3 cells that constitutively over- express the human IGF-1 receptor; Ref. 38) as well as in glo- merular mesangial cells (47). It also been demonstrated that overexpression and activation of IGF-1R protects cells from apoptosis induced by a variety of stimuli and conditions includ- ing IL-3 withdrawal (48, 49), Fas activation (50), osmotic shock (51, 52), tumor necrosis factor- ␣ (53), p53 (54), ionizing and nonionizing radiation (41), and okadaic treatment (55). How- ever, the mechanisms by which the IGF-1R protects cells from apoptosis have been the object of many investigations. Inhibi- tors of both PI3K and MAPK pathways have been shown to block the anti-apoptotic effects of IGF-1 (26, 41, 55). In Cos-7 cells, expression of activated Akt protects cells from apoptosis, whereas a kinase-dead Akt does not, suggesting that Akt is a target of PI3K in anti-apoptotic signaling of the IGF-1R (41).

One mechanism by which the activated Akt in response to IGF-1 may promote cell survival is though the inhibition of BAD, one component of the cell death machinery (56). How- ever, some studies show that the MAPK pathway can also phosphorylate BAD (57). The IGF-1R may also protect cells from apoptosis independently of BAD phosphorylation (55). In the present study, we show that a decrease of Twist expression by 40% in NWTb3 reduces significantly IGF-1’s ability to in- hibit apoptosis induced by etoposide. These data indicate that Twist could be a regulator in the anti-apoptotic actions of IGF-1. Maestro et al. (25) showed that, in C8 mouse embryo fibroblasts, Twist inhibits apoptosis by antagonizing the p53 pathway that plays a critical role in regulating cell death in response to a variety of stimuli. It has been shown that Twist can directly bind two independent histone acetyltransferase

3

A. M. Fernandez, J. Dupont, and D. LeRoith, submitted for publication.

F

. 6. Twist antisense expression interferes with IGF-1 inhi- bition of apoptosis induced by the etoposide treatment in NWTb3 cells. A, Twist protein expression in NWTb3 cells stably trans- fected with a Twist antisense construct (TWIAS). NWTb3 cells were stably transfected with pcDNA3 (hygro) or TWIAS constructs, as de- scribed under “Experimental Procedures.” 50 ␮ g of protein from whole cell lysates was subjected to SDS-PAGE, followed by immunoblotting with a rabbit Twist polyclonal antibody. Control cells are designated as hygro 1 and hygro 2. As a negative control, we used C2C12 cell lysates.

As control for the protein loading, the blot was stripped and reprobed with a mouse actin monoclonal antibody. B, IGF-1 treatment fails to rescue the apoptosis induced by etoposide in NWTb3 cells overexpress- ing Twist antisense cDNA. Control (hygro 1) and Twist antisense (TWIAS-2) cells were plated on 100-mm dishes in DMEM supplemented with 10% FBS. After 16 h of incubation, medium was changed to DMEM with 1% FBS, and cells were treated with etoposide (25 ␮

) as indi- cated. After 48 h of treatment, IGF-1 (10

) was added or not in the medium for 24 h. The cells were collected and analyzed by flow cytom- etry as described under “Experimental Procedures.” The error bars represent the mean ⫾ S.D. of percentage of apoptotic cells from three separate experiments. C, IGF-1 effects on the PARP cleavage in control and Twist antisense cells. Cells (hygro1 and TWIAS-2) were preincu- bated in DMEM with 1% FBS in the presence of etoposide (25 ␮

) for 48 h, and IGF-1 (10

) was added or not in the medium for 24 h. Cell lysates were subjected to Western blot analysis using an anti-PARP antibody as described under “Experimental Procedures.” These results are representative of two independent experiments.

Role of Twist in the Anti-apoptotic Actions of IGF-1R 26705

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

domains of acetyltransferases, p300 and p300/CBP-associated factor, and regulate their histone acetyltransferase activities (19). One hypothesis is that Twist may modulate p53 activity through effects on p300/CBP and p300/CBP-associated factor (25).

In summary, our results indicate that in NIH-3T3 fibroblasts

that overexpress human IGF-1 receptor (NWTb3 cells), IGF-1 induces Twist expression through activation of its receptor via the MEK/MAPK signaling pathway. We additionally demon- strate that a reduction in Twist expression impairs signifi- cantly the inhibition of IGF-1 on the apoptosis induced by F

. 7. Cell- and tissue-specific ex-

pression of Twist. A, serum-starved MCF-7, COS-7, NWTb3, C2C12, PC-3, and HEK 293 cells were incubated with IGF-1 (10

) for 90 min. Total RNA was extracted and analyzed by Northern blotting for the expression of Twist. 18 S ribosomal RNA is shown as loading con- trol. These results are representative of three independent experiments. B, mouse multiple tissues were Northern blot hybridized to a cDNA probe for Twist. 18 and 28 S ribosomal RNAs are shown as a control for the loading and the integrity of the RNAs.

F

. 8. Time course and dose effect of IGF-1 on Twist mRNA expression in mouse muscle. Three-week-old male C57BL/6j mice were infused for 20 min with either saline (0) or different concen- trations of rhIGF-1 (A) or with rhIGF-1 (2 mg/kg) for the time indicated (B) via the inferior vena cava after fasting overnight.

Muscles were removed from the leg and frozen in liquid nitrogen. Total RNA was extracted and analyzed by Northern blot- ting for Twist expression. After quantifi- cation by densitometry and autoradiogra- phy, membranes were stripped and reprobed with the 18 S ribosomal RNA for a loading control. The error bars repre- sent the mean ⫾ S.D. from four separate experiments.

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

etoposide. Thus, we identified a new component involved in the anti-apoptotic action of IGF-1 receptor. Finally, we show that IGF-1 also increases Twist expression in vivo in mouse skeletal muscle. Further investigation will enable us to discover the implications of these effects.

Acknowledgments—We thank Dr. J. S. Gutkind for giving us the dominant negative construct of MEK-1. We also thank Dr. S. Yakar for helpful discussions.

REFERENCES

1. Yarden, Y., and Ullrich, A. (1988)Biochemistry27,3113–3119 2. Ullrich, A., and Schlessinger, J. (1990)Cell61,203–212

3. Myers, M. G., Sun, X. J., Cheatham, B., Jachna, B. R., Glasheen, E. M., Backer, J. M., and White, M. F. (1993)Endocrinology132,1421–1430

4. Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995)Nature377,173–177 5. Lavan, B. E., and Lienhard, G. E. (1993)J. Biol. Chem.268,5921–5928 6. Fantin, V. R., Sparling, J. D., Slot, J. W., Keller, S. R., Lienhard, G. E., and

Lavan, B. E. (1998)J. Biol. Chem.273,10726 –10732

7. Winnay, J. N., Bruning, J. C., Burks, D. J., and Kahn, C. R. (2000)J. Biol.

Chem.275,10545–10550

8. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Pawson, T., and Pelicci, P. G. (1992)Cell70,93–104 9. Skolnik, E. Y., Lee, C. H., Batzer, A., Vicentini, L. M., Zhou, M., Daly, R.,

Myers, M. J., Backer, J. M., Ullrich, A., and White, M. F. (1993)EMBO J.

12,1929 –1936

10. Vanhaesebroeck, B., and Alessi, D. R. (2000)Biochem. J.346,561–576 11. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J., and Efstratiadis, A. (1993)

Cell75,59 –72

12. Di Cola, G., Cool, M. H., and Accili, D. (1997)J. Clin. Invest.99,2538 –2544 13. Cheatham, B., and Kahn, C. R. (1995)Endocr. Rev.16,117–142

14. LeRoith, D., Werner, H., Beitner-Johnson, D., and Roberts, C. T. (1995)En- docr. Rev.16,143–163

15. Olson, E. N., and Klein, W. H. (1994)Genes Dev.8,1– 8 16. Kadesch, T. (1993)Cell Growth Differ.4,49 –55

17. Thisse, B., Stoetzel, C., Gorostiza-Thisse, C., and Perrin-Schmitt, F. (1988) EMBO J.7,2175–2183

18. Spicer, D. B., Rhee, J., Cheung, W. L., and Lassar, A. B. (1996)Science272, 1476 –1480

19. Hamamori, Y., Wu, H. Y., Sartorelli, V., and Kedes, L. (1997)Mol. Cell. Biol.

17,6563– 6573

20. Murray, S. S., Glackin, C. A., Winters, K. A., Gazit, D., Kahn, A. J., and Murray, E. J. (1992)J. Bone Miner. Res.7,1131–1138

21. Lee, M. S., Lowe, G. N., Strong, D. D., Wergedal, J. E., and Glackin, C. A.

(1999)J. Cell. Biochem.75,566 –577

22. Hebrok, M., Wertz, K., and Fuchtbauer, E. M. (1994)Dev. Biol.165,537–544 23. Rohwedel, J., Horak, V., Hebrok, M., Fuchtbauer, E. M., and Wobus, A. M.

(1995)Exp. Cell Res.220,92–100

24. Leshem, Y., Spicer, D. B., Gal-Levi, R., and Halevy, O. (2000)J. Cell. Physiol.

184,101–109

25. Maestro, R., Dei Tos, A. P., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., and Hannon, G. J. (1999)Genes Dev.

13,2207–2217

26. Parrizas, M., Saltiel, A. R., and LeRoith, D. (1997)J. Biol. Chem.272,154 –161

27. McCubrey, J. A., Steelman, L. S., Mayo, M. W., Algate, P. A., Dellow, R. A., and Kaleko, M. (1991)Blood78,921–929

28. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. (1994)EMBO J.

13,3286 –3295

29. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. (1997)Cancer Res.

57,2687–2693

30. Hsing, A. Y., Kadomatsu, K., Bonham, M. J., and Danielpour, D. (1996)Cancer Res.56,5146 –5149

31. Blakesley, V., Kato, H., Roberts, C. T., and LeRoith, D. (1995)J. Biol. Chem.

270,2764 –2769

32. Kato, H., Faria, T. N., Stannard, B., Roberts, C. T., and LeRoith, D. (1993) J. Biol. Chem.268,2655–2661

33. Levy-Toledano, R., Accili, D., and Taylor, S. I. (1993)Biochim. Biophys. Acta 1220,1–14

34. Allen, R. T., Cluck, M. W., and Agrawal, D. K. (1998)Cell Mol. Life Sci.54, 427– 445

35. Qu, B. H., Karas, M., Koval, A., and LeRoith, D. (1999)J. Biol. Chem.274, 31179 –31184

36. Karas, M., Zaks, T. Z., Liu, J. L., and LeRoith, D. (1999)Mol. Biol. Cell10, 4441– 4450

37. Deleted in proof

38. Sell, C., Baserga, R., and Rubin, R. (1995)Cancer Res.55,303–306 39. van Engeland, M., Nieland, L. J., Ramaekers, F. C., Schutte, B., and

Reutelingsperger, C. P. (1998)Cytometry31,1–9

40. Coppola, D., Ferber, A., Miura, M., Sell, C., D’Ambrosio, C., Rubin, R., and Baserga, R. (1994)Mol. Cell. Biol.14,4588 – 4595

41. Kulik, G., Klippel, A., and Weber, M. J. (1997)Mol. Cell. Biol.17,1595–1606 42. Hebrok, M., Fuchtbauer, A., and Fuchtbauer, E. M. (1997)Exp. Cell Res.232,

295–303

43. Wang, S. M., Coljee, V. W., Pignolo, R. J., Rotenberg, M. O., Cristofalo, V. J., and Sierra, F. (1997)Gene(Amst.)187,83–92

44. Chen, Z. F., and Behringer, R. R. (1995)Genes Dev.9,686 – 699

45. Shishido, E., Higashijima, S., Emori, Y., and Saigo, K. (1993)Development117, 751–761

46. Bourez, R. L., Mathijssen, I. M., Vaandrager, J. M., and Vermeij-Keers, C.

(1997)J. Craniofac. Surg.8,441– 445

47. Mooney, A., Jobson, T., Bacon, R., Kitamura, M., and Savill, J. (1997)J. Im- munol.159,3949 –3960

48. O’Connor, R., Kauffmann-Zeh, A., Liu, Y., Lehar, S., Evan, G. I., Baserga, R., and Blattler, W. A. (1997)Mol. Cell. Biol.17,427– 435

49. Prisco, M., Hongo, A., Rizzo, M. G., Sacchi, A., and Baserga, R. (1997)Mol. Cell.

Biol.17,1084 –1092

50. Harrison, M., Dunger, A. M., Berg, S., Mabley, J., John, N., Green, M. H., and Green, I. C. (1998)FEBS Lett.435,207–210

51. Singleton, J. R., Dixit, V. M., and Feldman, E. L. (1996)J. Biol. Chem.271, 31791–31794

52. Mockridge, J. W., Benton, E. C., Andreeva, L. V., Latchman, D. S., Marber, M. S., and Heads, R. J. (2000)Biochem. Biophys. Res. Commun. 273, 322–327

53. Wu, Y., Tewari, M., Cui, S., and Rubin, R. (1996)J. Cell. Physiol.168,499 –509 54. D’Ambrosio, C., Valentinis, B., Prisco, M., Reiss, K., Rubini, M., and Baserga,

R. (1997)Cancer Res.57,3264 –3271

55. Kulik, G., and Weber, M. J. (1998)Mol. Cell. Biol.18,6711– 6718

56. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997)Cell91,231–241

57. Scheid, M. P., and Duronio, V. (1998)Proc. Natl. Acad. Sci. U. S. A.95, 7439 –7444

Role of Twist in the Anti-apoptotic Actions of IGF-1R 26707

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from

Joëlle Dupont, Ana M. Fernandez, Charlotta A. Glackin, Lee Helman and Derek LeRoith Anti-apoptotic Effects of the IGF-1 Receptor

Insulin-like Growth Factor 1 (IGF-1)-induced Twist Expression Is Involved in the

doi: 10.1074/jbc.M102664200 originally published online April 25, 2001 2001, 276:26699-26707.

J. Biol. Chem.

10.1074/jbc.M102664200 Access the most updated version of this article at doi:

Alerts:

When a correction for this article is posted

•

When this article is cited

•

to choose from all of JBC's e-mail alerts Click here

http://www.jbc.org/content/276/28/26699.full.html#ref-list-1

This article cites 56 references, 28 of which can be accessed free at

at INRA Institut National de la Recherche Agronomique on August 20, 2018 http://www.jbc.org/ Downloaded from